Skip to content
DataLookout
Menu

NCT05672147

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 3 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Sep 3, 2028 to Sep 3, 2031
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study description revised
  2. Notable Primary and study completion dates: Sep 3, 2026 to Sep 3, 2028v6
  3. Minor Start date changed from estimate of Dec 28, 2023 to Dec 7, 2023v5
  4. Notable Primary and study completion dates: Nov 13, 2025 to Sep 3, 2026
    • Start date: Nov 1, 2023 to Dec 28, 2023
    v4
  5. Notable Start date: Aug 13, 2023 to Nov 1, 2023v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 13, 2023 to Aug 13, 2023
    • Site details revised
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Participants who achieve measurable residual disease (MRD)
Timeframe: Up to 15 years post study treatment
Incidence of dose-limiting toxicities and full toxicity profile
Timeframe: Up to 1 year following the last CAR T cell infusion

Secondary (5)

Expansion and persistence of the CAR T cell product
Percent and counts from peripheral blood cell subsets in hematopoietic stem/progenitor cell compartments
Duration of response
Progression-free survival
Overall survival

Arms and interventions

Treatment (anti-CD33 CAR T-cells)Experimental

Patients undergo lymphodepletion therapy 3-5 days prior to CAR T cell infusion and receive anti-CD33 CAR T-cells IV on day 0. Patients with persistent CD33+ AML who are \> 28 days past the initial CAR T infusion, have additional product available and did not experience a dose-limiting toxicity, may optionally receive anti-CD33 CAR T-cells IV.

Biologicals: Anti-CD33 CAR T-cells

Procedures: Lymphodepletion Therapy

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States